B7‑H4 overexpression correlates with a poor prognosis for cervical cancer patients

Liu,Wenting; Shibata,Kiyosumi; Koya,Yoshihiro; Kajiyama,Hiroaki; Senga,Takeshi; Yamasitha,Mamoru; Kikkawa,Fumitaka

doi:10.3892/mco.2013.225

B7‑H4 overexpression correlates with a poor prognosis for cervical cancer patients

Authors:
- Wenting Liu
- Kiyosumi Shibata
- Yoshihiro Koya
- Hiroaki Kajiyama
- Takeshi Senga
- Mamoru Yamasitha
- Fumitaka Kikkawa
View Affiliations

Affiliations: Bell Research Center for Reproductive Health and Cancer, Kishokai Medical Corporation, Nagoya, Aichi 458‑0801, Japan, Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan, Bio‑Databases Institute of Reproductive and Developmental Medicine, Nagoya, Aichi 458‑0801, Japan, Division of Cancer Biology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466‑8550, Japan
Published online on: December 12, 2013 https://doi.org/10.3892/mco.2013.225
Pages: 219-225

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is a major global public health care concern and the second most commonly diagnosed malignancy among females worldwide. B7‑H4 is an immunoregulatory protein that has been shown to be overexpressed in several types of cancer and is often associated with more advanced disease and poor prognosis. We investigated whether B7‑H4 is a prognostic maker for cervical cancer by detecting its expression in cervical cancer specimens. Formalin‑fixed, paraffin‑embedded tissue blocks from cervical cancer were evaluated for B7‑H4 expression by immunohistochemistry with free R software analysis. The intensity of B7‑H4 immunoexpression was evaluated according to age, histological type, International Federation of Gynecology and Obstetrics (FIGO) stage, lymphovascular space invasion (LVSI) and lymph node status. We investigated the distribution and expression of B7‑H4 in 102 cervical cancer specimens and determined the association between its expression and clinicopathological characteristics, including patient outcomes. Of the 102 specimens, 31 were found to be negative for B7‑H4 immunoexpression, whereas 71 were B7‑H4‑positive. When classified by negative vs. positive expression, B7‑H4 was not found to be associated with any of the clinicopathological parameters investigated. A positive B7‑H4 expression significantly predicted poor overall survival (OS) when compared to negative expression (P<0.05). In the multivariate analysis, positive B7‑H4 expression was identified as an independent prognostic factor for OS (P<0.05). Our data suggested that positive B7‑H4 expression may be a useful biomarker in patients with cervical cancer likely to have an unfavorable clinical outcome.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
2	Shibata K, Kajiyama H, Ino K, et al: Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol. 19:81–85. 2008. View Article : Google Scholar : PubMed/NCBI
3	Sica GL, Choi IH, Zhu G, et al: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 18:849–861. 2003. View Article : Google Scholar : PubMed/NCBI
4	Fauci JM, Straughn JM Jr, Ferrone S and Buchsbaum DJ: A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol. 127:420–425. 2012. View Article : Google Scholar : PubMed/NCBI
5	Prasad DV, Richards S, Mai XM and Dong C: B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 18:863–873. 2003. View Article : Google Scholar : PubMed/NCBI
6	Zang X, Loke P, Kim J, Murphy K, Waitz R and Allison JP: B7×: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA. 100:10388–10392. 2003.
7	Krambeck AE, Thompson RH, Dong H, et al: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA. 103:10391–10396. 2006. View Article : Google Scholar : PubMed/NCBI
8	Kryczek I, Wei S, Zhu G, et al: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67:8900–8905. 2007. View Article : Google Scholar : PubMed/NCBI
9	Salceda S, Tang T, Kmet M, et al: The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 306:128–141. 2005. View Article : Google Scholar : PubMed/NCBI
10	Tringler B, Zhuo S, Pilkington G, et al: B7-H4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 11:1842–1848. 2005. View Article : Google Scholar : PubMed/NCBI
11	Tringler B, Liu W, Corral L, et al: B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 100:44–52. 2006. View Article : Google Scholar : PubMed/NCBI
12	Chen LJ, Sun J, Wu HY, et al: B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 60:1047–1055. 2011.PubMed/NCBI
13	Seliger B, Marincola FM, Ferrone S and Abken H: The complex role of B7 molecules in tumor immunology. Trends Mol Med. 14:550–559. 2008. View Article : Google Scholar : PubMed/NCBI
14	Quandt D, Fiedler E, Boettcher D, Marsch WCh and Seliger B: B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 17:3100–3111. 2011.PubMed/NCBI
15	Kryczek I, Zou L, Rodriguez P, et al: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 203:871–881. 2006. View Article : Google Scholar : PubMed/NCBI
16	Miyatake T, Tringler B, Liu W, et al: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol. 106:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
17	Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
18	Arigami T, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N and Natsugoe S: Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg. 35:2051–2057. 2011. View Article : Google Scholar : PubMed/NCBI
19	Simon I, Katsaros D, Rigault de la Longrais I, et al: B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol. 106:334–341. 2007. View Article : Google Scholar : PubMed/NCBI
20	Zang X, Thompson RH, Al-Ahmadie HA, et al: B7-H3 and B7× are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 104:19458–19463. 2007.
21	Galazka K, Oplawski M, Windorbska W, et al: The immunohistochemical analysis of antigens such as RCAS1 and B7H4 in the cervical cancer nest and within the fibroblasts and macrophages infiltrating the cancer microenvironment. Am J Reprod Immunol. 68:85–93. 2012. View Article : Google Scholar : PubMed/NCBI
22	Awadallah NS, Shroyer KR, Langer DA, et al: Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas. 36:200–206. 2008. View Article : Google Scholar : PubMed/NCBI
23	He C, Qiao H, Jiang H and Sun X: The inhibitory role of B7-H4 in antitumor immunity: association with cancer progression and survival. Clin Dev Immunol. 2011:6958342011.PubMed/NCBI
24	Cheng L, Jiang J, Gao R, et al: B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer. 19:1481–1486. 2009. View Article : Google Scholar : PubMed/NCBI
25	Hofmeyer KA, Scandiuzzi L, Ghosh K, Pirofski LA and Zang X: Tissue-expressed B7× affects the immune response to and outcome of lethal pulmonary infection. J Immunol. 189:3054–3063. 2012.
26	McGrath MM and Najafian N: The role of coinhibitory signaling pathways in transplantation and tolerance. Front Immunol. 3:472012. View Article : Google Scholar : PubMed/NCBI
27	Wang X, Hao J, Metzger DL, et al: B7-H4 treatment of T cells inhibits ERK, JNK, p38, and AKT activation. PLoS One. 7:e282322012. View Article : Google Scholar : PubMed/NCBI